Chad M Robins Adaptive Biotechnologies Corp (ADPT) insider trading activity

Chad M Robins is CEO and Chairman of Adaptive Biotechnologies Corp. Currently has a direct ownership of 2.96 Million shares of ADPT, which is worth approximately $22.7 Million. The most recent transaction as insider was on Sep 10, 2021, when has been sold 5,000 shares (Common Stock) at a price of $38.73 per share, resulting in proceeds of $193,650. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.96M

14.85% 3M change

14.85% 12M change

Total Value Held $22.7 Million

CHAD M ROBINS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 10 2021	SELL Open market or private sale	$193,650 $38.73 p/Share	5,000 Reduced 0.3%	1,673,461 Common Stock
Sep 09 2021	SELL Open market or private sale	$951,010 $38.42 p/Share	24,753 Reduced 1.45%	1,678,461 Common Stock
Sep 08 2021	SELL Open market or private sale	$532,383 $38.73 p/Share	13,746 Reduced 0.8%	1,703,214 Common Stock
Jul 12 2021	SELL Open market or private sale	$57,398 $38.24 p/Share	1,501 Reduced 0.09%	1,716,960 Common Stock
Jun 17 2021	SELL Open market or private sale	$205,733 $39.15 p/Share	5,255 Reduced 0.3%	1,718,461 Common Stock
Jun 16 2021	SELL Open market or private sale	$180,927 $38.13 p/Share	4,745 Reduced 0.27%	1,723,716 Common Stock
Jun 15 2021	SELL Open market or private sale	$774,600 $38.73 p/Share	20,000 Reduced 1.14%	1,728,461 Common Stock
Apr 08 2021	SELL Open market or private sale	$214,700 $42.94 p/Share	5,000 Reduced 0.29%	1,748,461 Common Stock
Apr 07 2021	SELL Open market or private sale	$205,150 $41.03 p/Share	5,000 Reduced 0.28%	1,753,461 Common Stock
Apr 06 2021	SELL Open market or private sale	$211,050 $42.21 p/Share	5,000 Reduced 0.28%	1,758,461 Common Stock
Mar 19 2021	SELL Open market or private sale	$211,100 $42.22 p/Share	5,000 Reduced 0.28%	1,763,461 Common Stock
Mar 18 2021	SELL Open market or private sale	$214,150 $42.83 p/Share	5,000 Reduced 0.28%	1,768,461 Common Stock
Mar 17 2021	SELL Open market or private sale	$220,850 $44.17 p/Share	5,000 Reduced 0.28%	1,773,461 Common Stock
Mar 04 2021	BUY Grant, award, or other acquisition	-	68,681 Added 3.72%	1,778,461 Common Stock
Feb 10 2021	SELL Open market or private sale	$629,000 $62.9 p/Share	10,000 Reduced 0.58%	1,709,780 Common Stock
Feb 09 2021	SELL Open market or private sale	$626,500 $62.65 p/Share	10,000 Reduced 0.58%	1,719,780 Common Stock
Feb 08 2021	SELL Open market or private sale	$618,000 $61.8 p/Share	10,000 Reduced 0.57%	1,729,780 Common Stock
Jan 28 2021	SELL Open market or private sale	$565,300 $56.53 p/Share	10,000 Reduced 0.57%	1,739,780 Common Stock
Jan 27 2021	SELL Open market or private sale	$574,200 $57.42 p/Share	10,000 Reduced 0.57%	1,749,780 Common Stock
Jan 26 2021	SELL Open market or private sale	$639,700 $63.97 p/Share	10,000 Reduced 0.57%	1,759,780 Common Stock
Jan 19 2021	SELL Open market or private sale	$594,552 $70.78 p/Share	8,400 Reduced 0.47%	1,769,780 Common Stock
Dec 30 2020	SELL Open market or private sale	$981,784 $59.43 p/Share	16,520 Reduced 0.92%	1,778,180 Common Stock
Dec 30 2020	BUY Exercise of conversion of derivative security	$5,452 $0.33 p/Share	16,520 Added 0.91%	1,794,700 Common Stock
Dec 29 2020	SELL Open market or private sale	$1,001,859 $59.67 p/Share	16,790 Reduced 0.94%	1,778,180 Common Stock
Dec 29 2020	BUY Exercise of conversion of derivative security	$5,541 $0.33 p/Share	16,790 Added 0.93%	1,794,970 Common Stock

CMR

Chad M Robins

CEO and Chairman

Seattle, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Value

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT

Account